Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
24
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| KNOBELMAN DEBORAH | President & Interim CEO | 5 | $0 | $21.6K | 2025-06-20 |
| Stultz Katherine V | Director | 6 | $0 | $0 | 2025-06-20 |
| Blunt Roshawn A. | Director | 8 | $0 | $0 | 2025-06-20 |
| Ridloff Elena | Director | 14 | $50.0K | $0 | 2025-06-20 |
| DANSEY ROGER D | Director | 6 | $0 | $0 | 2025-06-20 |
| Yang Taiyin | Director | 12 | $0 | $0 | 2025-06-20 |
| Belldegrun Arie | Director | 20 | $0 | $0 | 2025-06-20 |
| Kazam Joshua A | Director | 15 | $0 | $0 | 2025-06-20 |
| BISCHOFBERGER NORBERT W | President & CEO | 42 | $9.56M | $0 | 2025-06-20 |
| TANEN DAVID M | Director | 23 | $0 | $0 | 2025-06-20 |
| Lin Charles Y | SR VP, RESEARCH & DEVELOPMENT | 2 | $0 | $12.6K | 2024-10-15 |
| Frisbee Allison | SR VP, CORP OPERATIONS & LEGAL | 2 | $0 | $12.7K | 2024-10-15 |
| Olek Elizabeth A | SR VP, CLINICAL SCIENCE | 1 | $0 | $7.7K | 2024-02-21 |
| Dinsmore Christopher | Chief Scientific Officer | 24 | $99.8K | $783.5K | 2024-01-04 |
| DiMartino Jorge | Chief Medical Officer & VP | 14 | $0 | $310.1K | 2024-01-04 |
| Kosacz Barbara | COO & General Counsel | 9 | $99.8K | $12.6K | 2024-01-04 |
| Al-Wakeel Yasir B. | Chief Financial Officer | 11 | $99.8K | $32.5K | 2023-07-06 |
| De Backer Marianne | Director | 9 | $47.9K | $0 | 2023-06-22 |
| Stampacchia Otello | Director, 10% Owner | 9 | $8.55M | $0 | 2022-06-22 |
| Loven Jakob | Director | 21 | $0 | $5.84M | 2021-04-20 |
| Belldegrun Rebecka | Director | 4 | $0 | $0 | 2020-10-14 |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10% Owner | 7 | $1.81M | $0 | 2020-10-14 |
| Nessi Claudio | 10% Owner | 7 | $8.55M | $0 | 2020-10-14 |
| MARTIN JOHN C | Director | 7 | $1.44M | $0 | 2020-10-14 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| KNOBELMAN DEBORAH | President & Interim CEO | D To issuer deriv | 2025-06-20 | 2025-06-20 | 246,390 | — | $0 | 0 | SEC↗ |
| Stultz Katherine V | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Stultz Katherine V | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 7,079 | — | $0 | 0 | SEC↗ |
| Stultz Katherine V | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 68,000 | — | $0 | 0 | SEC↗ |
| Yang Taiyin | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Yang Taiyin | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 5,150 | — | $0 | 0 | SEC↗ |
| Yang Taiyin | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 41,200 | — | $0 | 0 | SEC↗ |
| Yang Taiyin | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 17,000 | — | $0 | 0 | SEC↗ |
| Yang Taiyin | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| DANSEY ROGER D | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 5,868 | — | $0 | 0 | SEC↗ |
| DANSEY ROGER D | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 68,000 | — | $0 | 0 | SEC↗ |
| DANSEY ROGER D | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Kazam Joshua A | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Kazam Joshua A | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 20,600 | — | $0 | 0 | SEC↗ |
| Kazam Joshua A | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Kazam Joshua A | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Blunt Roshawn A. | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Blunt Roshawn A. | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 41,200 | — | $0 | 0 | SEC↗ |
| Blunt Roshawn A. | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Blunt Roshawn A. | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 19,892 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 85,608 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 20,600 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 20,600 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Ridloff Elena | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 17,000 | — | $0 | 0 | SEC↗ |
| Ridloff Elena | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 25,879 | — | $0 | 0 | SEC↗ |
| Ridloff Elena | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 26,871 | — | $0 | 0 | SEC↗ |
| Ridloff Elena | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 15,450 | — | $0 | 0 | SEC↗ |
| Ridloff Elena | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 34,000 | — | $0 | 0 | SEC↗ |
| Ridloff Elena | Director | D To issuer deriv | 2025-06-20 | 2025-06-20 | 17,000 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | D To issuer deriv | 2025-06-20 | 2025-06-20 | 699,800 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | D To issuer deriv | 2025-06-20 | 2025-06-20 | 297,186 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | D To issuer deriv | 2025-06-20 | 2025-06-20 | 400,000 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | D To issuer deriv | 2025-06-20 | 2025-06-20 | 570,868 | — | $0 | 0 | SEC↗ |
| KNOBELMAN DEBORAH | President & Interim CEO | U Tender | 2025-06-20 | 2025-06-20 | 139,422 | $0.57 | $79.5K | 0 | SEC↗ |
| Yang Taiyin | Director | U Tender | 2025-06-20 | 2025-06-20 | 11,333 | $0.57 | $6.5K | 0 | SEC↗ |
| Kazam Joshua A | Director | U Tender | 2025-06-20 | 2025-06-20 | 94,481 | $0.57 | $53.9K | 0 | SEC↗ |
| TANEN DAVID M | Director | U Tender | 2025-06-20 | 2025-06-20 | 363,428 | $0.57 | $207.2K | 0 | SEC↗ |
| TANEN DAVID M | Director | U Tender | 2025-06-20 | 2025-06-20 | 471,230 | $0.57 | $268.6K | 0 | SEC↗ |
| TANEN DAVID M | Director | U Tender | 2025-06-20 | 2025-06-20 | 26,375 | $0.57 | $15.0K | 0 | SEC↗ |
| TANEN DAVID M | Director | U Tender | 2025-06-20 | 2025-06-20 | 26,375 | $0.57 | $15.0K | 0 | SEC↗ |
| TANEN DAVID M | Director | U Tender | 2025-06-20 | 2025-06-20 | 26,375 | $0.57 | $15.0K | 0 | SEC↗ |
| Belldegrun Arie | Director | U Tender | 2025-06-20 | 2025-06-20 | 2,765,314 | $0.57 | $1.58M | 0 | SEC↗ |
| Belldegrun Arie | Director | U Tender | 2025-06-20 | 2025-06-20 | 679,575 | $0.57 | $387.4K | 0 | SEC↗ |
| Ridloff Elena | Director | U Tender | 2025-06-20 | 2025-06-20 | 25,296 | $0.57 | $14.4K | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | U Tender | 2025-06-20 | 2025-06-20 | 263,750 | $0.57 | $150.3K | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | U Tender | 2025-06-20 | 2025-06-20 | 263,750 | $0.57 | $150.3K | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | U Tender | 2025-06-20 | 2025-06-20 | 10,802,138 | $0.57 | $6.16M | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | U Tender | 2025-06-20 | 2025-06-20 | 263,750 | $0.57 | $150.3K | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | Director, 10% Owner | U Tender | 2025-06-20 | 2025-06-20 | 263,750 | $0.57 | $150.3K | 0 | SEC↗ |
| KNOBELMAN DEBORAH | President & Interim CEO | S Sale | 2025-06-05 | 2025-06-06 | 24,838 | $0.87 | $21.6K | 139,422 | SEC↗ |
| Lin Charles Y | Chief Scientific Officer | A Award deriv | 2024-10-15 | 2024-10-15 | 72,900 | — | $0 | 72,900 | SEC↗ |
| Frisbee Allison | Chief Administrative Officer | A Award deriv | 2024-10-15 | 2024-10-15 | 72,900 | — | $0 | 72,900 | SEC↗ |
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | P Buy | 2024-06-28 | 2024-07-01 | 204,670 | $1.25 | $255.8K | 10,802,138 | SEC↗ |
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | P Buy | 2024-06-27 | 2024-07-01 | 410,848 | $1.17 | $480.7K | 10,597,468 | SEC↗ |
| TANEN DAVID M | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Belldegrun Arie | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Kazam Joshua A | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Blunt Roshawn A. | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Yang Taiyin | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Stultz Katherine V | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| DANSEY ROGER D | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Ridloff Elena | Director | A Award deriv | 2024-06-25 | 2024-06-26 | 17,000 | — | $0 | 17,000 | SEC↗ |
| Ridloff Elena | Director | A Award | 2024-06-25 | 2024-06-26 | 11,333 | — | $0 | 25,296 | SEC↗ |
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | P Buy | 2024-06-12 | 2024-06-12 | 881,913 | $1.24 | $1.09M | 7,375,616 | SEC↗ |
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | P Buy | 2024-06-11 | 2024-06-12 | 744,308 | $1.09 | $811.3K | 6,493,703 | SEC↗ |
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | P Buy | 2024-06-10 | 2024-06-12 | 1,378,901 | $0.88 | $1.21M | 5,749,395 | SEC↗ |
| KNOBELMAN DEBORAH | Chief Financial Officer | A Award deriv | 2024-06-03 | 2024-06-04 | 246,390 | — | $0 | 246,390 | SEC↗ |
| KNOBELMAN DEBORAH | Chief Financial Officer | A Award | 2024-06-03 | 2024-06-04 | 164,260 | — | $0 | 164,260 | SEC↗ |
| Frisbee Allison | SR VP, CORP OPERATIONS & LEG | S Sale | 2024-02-21 | 2024-02-23 | 12,105 | $1.05 | $12.7K | 204,510 | SEC↗ |
| Lin Charles Y | SR VP, RESEARCH & DEVELOPMEN | S Sale | 2024-02-21 | 2024-02-23 | 12,036 | $1.05 | $12.6K | 234,603 | SEC↗ |
| Olek Elizabeth A | SR VP, CLINICAL SCIENCE | S Sale | 2024-02-21 | 2024-02-23 | 7,368 | $1.05 | $7.7K | 193,275 | SEC↗ |
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | A Award deriv | 2024-02-15 | 2024-02-16 | 699,800 | — | $0 | 699,800 | SEC↗ |
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | A Award | 2024-02-15 | 2024-02-16 | 270,339 | — | $0 | 2,811,004 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | S Sale | 2024-01-04 | 2024-01-05 | 10,676 | $1.18 | $12.6K | 928,966 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | S Sale | 2024-01-04 | 2024-01-05 | 12,009 | $1.18 | $14.2K | 315,246 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2024-01-04 | 2024-01-05 | 7,366 | $1.18 | $8.7K | 260,969 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | S Sale | 2023-12-12 | 2023-12-13 | 17,367 | $1.31 | $22.8K | 327,255 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2023-12-12 | 2023-12-13 | 10,032 | $1.31 | $13.1K | 268,335 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2023-11-17 | 2023-11-17 | 97,935 | $1.08 | $105.8K | 2,540,665 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2023-11-16 | 2023-11-17 | 262,433 | $1.00 | $262.4K | 2,442,730 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2023-11-15 | 2023-11-17 | 1,370,688 | $0.80 | $1.10M | 2,180,297 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | S Sale | 2023-07-06 | 2023-07-07 | 9,617 | $1.75 | $16.8K | 346,102 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | S Sale | 2023-07-06 | 2023-07-07 | 10,818 | $1.75 | $18.9K | 344,622 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2023-07-06 | 2023-07-07 | 6,634 | $1.75 | $11.6K | 278,367 | SEC↗ |
| Belldegrun Arie | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| TANEN DAVID M | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Kazam Joshua A | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| De Backer Marianne | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Blunt Roshawn A. | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Yang Taiyin | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Stultz Katherine V | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 7,079 | — | $0 | 7,079 | SEC↗ |
| DANSEY ROGER D | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 5,868 | — | $0 | 5,868 | SEC↗ |
| Ridloff Elena | Director | A Award deriv | 2023-06-22 | 2023-06-26 | 17,000 | — | $0 | 17,000 | SEC↗ |
| Ridloff Elena | Director | A Award | 2023-06-22 | 2023-06-26 | 11,333 | — | $0 | 13,963 | SEC↗ |
| DANSEY ROGER D | Director | A Award deriv | 2023-04-20 | 2023-04-24 | 68,000 | — | $0 | 68,000 | SEC↗ |
| Stultz Katherine V | Director | A Award deriv | 2023-04-10 | 2023-04-11 | 68,000 | — | $0 | 68,000 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | S Sale | 2023-02-24 | 2023-02-24 | 9,026 | $1.74 | $15.7K | 355,719 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | S Sale | 2023-02-24 | 2023-02-24 | 10,153 | $1.74 | $17.7K | 355,440 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2023-02-24 | 2023-02-24 | 6,291 | $1.74 | $10.9K | 285,001 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | A Award deriv | 2023-02-15 | 2023-02-17 | 570,868 | — | $0 | 570,868 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award deriv | 2023-02-15 | 2023-02-17 | 208,367 | — | $0 | 208,367 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | A Award deriv | 2023-02-15 | 2023-02-17 | 205,513 | — | $0 | 205,513 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | A Award deriv | 2023-02-15 | 2023-02-17 | 208,367 | — | $0 | 208,367 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | A Award deriv | 2023-02-15 | 2023-02-17 | 179,824 | — | $0 | 179,824 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award | 2023-02-15 | 2023-02-17 | 138,911 | — | $0 | 364,745 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | A Award | 2023-02-15 | 2023-02-17 | 137,008 | — | $0 | 365,593 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | A Award | 2023-02-15 | 2023-02-17 | 138,911 | — | $0 | 939,642 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | A Award | 2023-02-15 | 2023-02-17 | 119,882 | — | $0 | 291,292 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2022-12-12 | 2022-12-14 | 9,138 | $1.81 | $16.5K | 162,936 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | S Sale | 2022-12-12 | 2022-12-14 | 18,657 | $1.81 | $33.8K | 219,478 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award deriv | 2022-07-25 | 2022-07-27 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | A Award | 2022-07-25 | 2022-07-27 | 53,600 | — | $0 | 791,624 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | A Award | 2022-07-25 | 2022-07-27 | 60,300 | — | $0 | 238,135 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | A Award | 2022-07-25 | 2022-07-27 | 43,550 | — | $0 | 172,074 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award | 2022-07-25 | 2022-07-27 | 53,600 | — | $0 | 216,841 | SEC↗ |
| Belldegrun Arie | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 34,000 | — | $0 | 34,000 | SEC↗ |
| TANEN DAVID M | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Kazam Joshua A | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Ridloff Elena | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Stampacchia Otello | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 34,000 | — | $0 | 34,000 | SEC↗ |
| Blunt Roshawn A. | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 34,000 | — | $0 | 34,000 | SEC↗ |
| De Backer Marianne | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 17,000 | — | $0 | 17,000 | SEC↗ |
| Yang Taiyin | Director | A Award deriv | 2022-06-22 | 2022-06-29 | 17,000 | — | $0 | 17,000 | SEC↗ |
| De Backer Marianne | Director | A Award | 2022-06-22 | 2022-06-29 | 11,333 | — | $0 | 14,083 | SEC↗ |
| Yang Taiyin | Director | A Award | 2022-06-22 | 2022-06-29 | 11,333 | — | $0 | 11,333 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2022-05-19 | 2022-05-19 | 300,000 | $3.78 | $1.13M | 809,609 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2022-05-18 | 2022-05-19 | 206,198 | $3.72 | $767.1K | 509,609 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2022-05-17 | 2022-05-19 | 90,931 | $3.83 | $348.3K | 303,411 | SEC↗ |
| Kazam Joshua A | Director | G Gift | 2022-03-07 | 2022-03-09 | 211,000 | — | $0 | 305,481 | SEC↗ |
| Kazam Joshua A | Director | G Gift | 2022-03-07 | 2022-03-09 | 211,000 | — | $0 | 94,481 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | A Award deriv | 2022-02-16 | 2022-02-17 | 400,000 | — | $0 | 400,000 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award deriv | 2022-02-15 | 2022-02-17 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | A Award deriv | 2022-02-15 | 2022-02-17 | 65,000 | — | $0 | 65,000 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | A Award deriv | 2022-02-15 | 2022-02-17 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | A Award deriv | 2022-02-15 | 2022-02-17 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award | 2022-02-15 | 2022-02-17 | 53,600 | — | $0 | 163,241 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | A Award | 2022-02-15 | 2022-02-17 | 43,550 | — | $0 | 128,524 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | A Award | 2022-02-15 | 2022-02-17 | 60,300 | — | $0 | 177,835 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | A Award | 2022-02-15 | 2022-02-17 | 53,600 | — | $0 | 738,024 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | S Sale | 2021-12-13 | 2021-12-15 | 16,152 | $12.36 | $199.6K | 117,785 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | S Sale | 2021-12-13 | 2021-12-15 | 250 | $12.82 | $3.2K | 117,535 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2021-12-13 | 2021-12-15 | 11,212 | $12.36 | $138.6K | 85,148 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2021-12-13 | 2021-12-15 | 174 | $12.82 | $2.2K | 84,974 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2021-12-06 | 2021-12-08 | 14,356 | $12.09 | $173.6K | 212,480 | SEC↗ |
| De Backer Marianne | Director | P Buy | 2021-12-01 | 2021-12-02 | 1,150 | $11.57 | $13.3K | 2,750 | SEC↗ |
| Blunt Roshawn A. | Director | A Award deriv | 2021-11-11 | 2021-11-15 | 41,200 | — | $0 | 41,200 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | M Exercise deriv | 2021-10-04 | 2021-10-04 | 9,189 | — | $0 | 315,308 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | M Exercise | 2021-10-04 | 2021-10-04 | 9,189 | $3.27 | $30.0K | 105,549 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2021-10-04 | 2021-10-04 | 9,189 | $20.81 | $191.2K | 96,360 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | M Exercise deriv | 2021-09-07 | 2021-09-09 | 9,189 | — | $0 | 324,497 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | M Exercise | 2021-09-07 | 2021-09-09 | 9,189 | $3.27 | $30.0K | 105,549 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2021-09-07 | 2021-09-09 | 9,189 | $21.91 | $201.3K | 96,360 | SEC↗ |
| De Backer Marianne | Director | P Buy | 2021-08-20 | 2021-08-24 | 500 | $19.50 | $9.8K | 1,100 | SEC↗ |
| De Backer Marianne | Director | P Buy | 2021-08-20 | 2021-08-24 | 500 | $19.63 | $9.8K | 1,600 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | M Exercise deriv | 2021-08-02 | 2021-08-03 | 9,189 | — | $0 | 333,686 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | M Exercise | 2021-08-02 | 2021-08-03 | 9,189 | $3.27 | $30.0K | 105,549 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | S Sale | 2021-08-02 | 2021-08-03 | 9,189 | $20.59 | $189.2K | 96,360 | SEC↗ |
| TANEN DAVID M | Director | A Award deriv | 2021-06-22 | 2021-06-23 | 20,600 | — | $0 | 20,600 | SEC↗ |
| Belldegrun Arie | Director | A Award deriv | 2021-06-22 | 2021-06-23 | 20,600 | — | $0 | 20,600 | SEC↗ |
| Kazam Joshua A | Director | A Award deriv | 2021-06-22 | 2021-06-23 | 20,600 | — | $0 | 20,600 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | A Award deriv | 2021-06-22 | 2021-06-23 | 20,600 | — | $0 | 20,600 | SEC↗ |
| Ridloff Elena | Director | A Award deriv | 2021-06-22 | 2021-06-23 | 15,450 | — | $0 | 15,450 | SEC↗ |
| De Backer Marianne | Director | A Award deriv | 2021-06-22 | 2021-06-23 | 8,583 | — | $0 | 8,583 | SEC↗ |
| Yang Taiyin | Director | A Award deriv | 2021-06-22 | 2021-06-23 | 5,150 | — | $0 | 5,150 | SEC↗ |
| De Backer Marianne | Director | P Buy | 2021-05-28 | 2021-06-01 | 600 | $25.01 | $15.0K | 600 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-20 | 2021-04-20 | 21,532 | $20.10 | $432.8K | 1,301,556 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-20 | 2021-04-20 | 19 | $20.63 | $392 | 1,301,537 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-19 | 2021-04-20 | 4,157 | $21.38 | $88.9K | 1,323,088 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-19 | 2021-04-20 | 9,847 | $20.25 | $199.4K | 1,327,245 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-16 | 2021-04-20 | 7,870 | $21.56 | $169.7K | 1,337,092 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-16 | 2021-04-20 | 25,292 | $20.84 | $527.1K | 1,344,962 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-15 | 2021-04-15 | 24,818 | $21.78 | $540.5K | 1,370,254 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-14 | 2021-04-15 | 13,698 | $22.38 | $306.6K | 1,414,010 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-14 | 2021-04-15 | 18,938 | $23.10 | $437.5K | 1,395,072 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-13 | 2021-04-15 | 5,738 | $24.40 | $140.0K | 1,428,993 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-13 | 2021-04-15 | 9,997 | $23.35 | $233.4K | 1,434,731 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-13 | 2021-04-15 | 1,285 | $25.18 | $32.4K | 1,427,708 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-12 | 2021-04-12 | 15,728 | $26.27 | $413.2K | 1,444,828 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-12 | 2021-04-12 | 100 | $27.21 | $2.7K | 1,444,728 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-09 | 2021-04-12 | 21,660 | $27.20 | $589.2K | 1,460,556 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-08 | 2021-04-12 | 24,816 | $27.91 | $692.6K | 1,482,216 | SEC↗ |
| Loven Jakob | Director | S Sale | 2021-04-08 | 2021-04-12 | 38,312 | $27.09 | $1.04M | 1,507,032 | SEC↗ |
| Yang Taiyin | Director | A Award deriv | 2021-03-25 | 2021-03-26 | 41,200 | — | $0 | 41,200 | SEC↗ |
| De Backer Marianne | Director | A Award deriv | 2021-01-25 | 2021-01-27 | 41,200 | — | $0 | 41,200 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | A Award deriv | 2020-12-10 | 2020-12-11 | 297,186 | — | $0 | 297,186 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | A Award | 2020-12-10 | 2020-12-11 | 198,124 | — | $0 | 198,124 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award deriv | 2020-12-09 | 2020-12-11 | 108,633 | — | $0 | 108,633 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | A Award deriv | 2020-12-09 | 2020-12-11 | 200,906 | — | $0 | 200,906 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | A Award deriv | 2020-12-09 | 2020-12-11 | 136,665 | — | $0 | 136,665 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | A Award deriv | 2020-12-09 | 2020-12-11 | 104,736 | — | $0 | 104,736 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | A Award | 2020-12-09 | 2020-12-11 | 72,422 | — | $0 | 109,641 | SEC↗ |
| DiMartino Jorge | Chief Medical Officer & VP | A Award | 2020-12-09 | 2020-12-11 | 133,937 | — | $0 | 133,937 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | A Award | 2020-12-09 | 2020-12-11 | 91,110 | — | $0 | 96,360 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | A Award | 2020-12-09 | 2020-12-11 | 69,824 | — | $0 | 684,424 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,565,475 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion deriv | 2020-10-14 | 2020-10-16 | 300,001 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion deriv | 2020-10-14 | 2020-10-16 | 250,000 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion deriv | 2020-10-14 | 2020-10-16 | 250,000 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion deriv | 2020-10-14 | 2020-10-16 | 250,000 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion deriv | 2020-10-14 | 2020-10-16 | 250,000 | — | $0 | 0 | SEC↗ |
| Bischofberger Norbert W. & Ing | 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| Bischofberger Norbert W. & Ing | 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 300,001 | — | $0 | 0 | SEC↗ |
| Bischofberger Norbert W. & Ing | 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,565,475 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 173,333 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,304,563 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 650,000 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 228,315 | — | $0 | 0 | SEC↗ |
| Belldegrun Arie | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| Belldegrun Rebecka | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 173,333 | — | $0 | 0 | SEC↗ |
| Belldegrun Rebecka | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 228,315 | — | $0 | 0 | SEC↗ |
| Kazam Joshua A | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 65,228 | — | $0 | 0 | SEC↗ |
| Kazam Joshua A | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 22,328 | — | $0 | 0 | SEC↗ |
| Loven Jakob | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| Loven Jakob | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,304,563 | — | $0 | 0 | SEC↗ |
| MARTIN JOHN C | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 717,509 | — | $0 | 0 | SEC↗ |
| MARTIN JOHN C | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 866,667 | — | $0 | 0 | SEC↗ |
| MARTIN JOHN C | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 65,243 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 221,237 | — | $0 | 0 | SEC↗ |
| TANEN DAVID M | Director | C Conversion deriv | 2020-10-14 | 2020-10-16 | 219,482 | — | $0 | 0 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,522,484 | — | $0 | 0 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,304,563 | — | $0 | 0 | SEC↗ |
| Nessi Claudio | 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 0 | — | $0 | 0 | SEC↗ |
| Nessi Claudio | 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,304,563 | — | $0 | 0 | SEC↗ |
| Nessi Claudio | 10% Owner | C Conversion deriv | 2020-10-14 | 2020-10-16 | 1,522,484 | — | $0 | 0 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion | 2020-10-14 | 2020-10-16 | 316,501 | — | $0 | 2,437,662 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | P Buy | 2020-10-14 | 2020-10-16 | 95,500 | $19.00 | $1.81M | 4,370,496 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion | 2020-10-14 | 2020-10-16 | 185,758 | $16.15 | $3.00M | 4,274,996 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion | 2020-10-14 | 2020-10-16 | 1,651,576 | — | $0 | 4,089,238 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion | 2020-10-14 | 2020-10-16 | 263,750 | — | $0 | 263,750 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion | 2020-10-14 | 2020-10-16 | 263,750 | — | $0 | 263,750 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion | 2020-10-14 | 2020-10-16 | 263,750 | — | $0 | 263,750 | SEC↗ |
| BISCHOFBERGER NORBERT W | President & CEO | C Conversion | 2020-10-14 | 2020-10-16 | 263,750 | — | $0 | 263,750 | SEC↗ |
| Bischofberger Norbert W. & Ing | 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 1,651,576 | — | $0 | 4,089,238 | SEC↗ |
| Bischofberger Norbert W. & Ing | 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 185,758 | $16.15 | $3.00M | 4,274,996 | SEC↗ |
| Bischofberger Norbert W. & Ing | 10% Owner | P Buy | 2020-10-14 | 2020-10-16 | 95,500 | $19.00 | $1.81M | 4,370,496 | SEC↗ |
| Bischofberger Norbert W. & Ing | 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 316,501 | — | $0 | 2,437,662 | SEC↗ |
| Al-Wakeel Yasir B. | Chief Financial Officer | P Buy | 2020-10-14 | 2020-10-16 | 5,250 | $19.00 | $99.8K | 37,219 | SEC↗ |
| Dinsmore Christopher | Chief Scientific Officer | P Buy | 2020-10-14 | 2020-10-16 | 5,250 | $19.00 | $99.8K | 5,250 | SEC↗ |
| Kosacz Barbara | COO & General Counsel | P Buy | 2020-10-14 | 2020-10-16 | 5,250 | $19.00 | $99.8K | 614,600 | SEC↗ |
| Belldegrun Arie | Director | C Conversion | 2020-10-14 | 2020-10-16 | 685,750 | — | $0 | 685,750 | SEC↗ |
| Belldegrun Arie | Director | C Conversion | 2020-10-14 | 2020-10-16 | 1,376,313 | — | $0 | 2,062,063 | SEC↗ |
| Belldegrun Arie | Director | C Conversion | 2020-10-14 | 2020-10-16 | 253,251 | $16.15 | $4.09M | 2,315,314 | SEC↗ |
| Belldegrun Arie | Director | C Conversion | 2020-10-14 | 2020-10-16 | 240,872 | — | $0 | 679,575 | SEC↗ |
| Belldegrun Arie | Director | C Conversion | 2020-10-14 | 2020-10-16 | 182,866 | — | $0 | 438,703 | SEC↗ |
| Belldegrun Rebecka | Director | C Conversion | 2020-10-14 | 2020-10-16 | 182,866 | — | $0 | 438,703 | SEC↗ |
| Belldegrun Rebecka | Director | C Conversion | 2020-10-14 | 2020-10-16 | 240,872 | — | $0 | 679,575 | SEC↗ |
| Kazam Joshua A | Director | C Conversion | 2020-10-14 | 2020-10-16 | 23,556 | — | $0 | 25,666 | SEC↗ |
| Kazam Joshua A | Director | C Conversion | 2020-10-14 | 2020-10-16 | 68,815 | — | $0 | 94,481 | SEC↗ |
| Loven Jakob | Director | C Conversion | 2020-10-14 | 2020-10-16 | 1,376,313 | — | $0 | 1,376,313 | SEC↗ |
| Loven Jakob | Director | C Conversion | 2020-10-14 | 2020-10-16 | 169,031 | $16.15 | $2.73M | 1,545,344 | SEC↗ |
| MARTIN JOHN C | Director | C Conversion | 2020-10-14 | 2020-10-16 | 756,971 | — | $0 | 1,671,304 | SEC↗ |
| MARTIN JOHN C | Director | C Conversion | 2020-10-14 | 2020-10-16 | 205,260 | $16.15 | $3.31M | 1,876,564 | SEC↗ |
| MARTIN JOHN C | Director | P Buy | 2020-10-14 | 2020-10-16 | 75,800 | $19.00 | $1.44M | 1,952,364 | SEC↗ |
| MARTIN JOHN C | Director | C Conversion | 2020-10-14 | 2020-10-16 | 914,333 | — | $0 | 914,333 | SEC↗ |
| Ridloff Elena | Director | P Buy | 2020-10-14 | 2020-10-16 | 2,630 | $19.00 | $50.0K | 2,630 | SEC↗ |
| TANEN DAVID M | Director | C Conversion | 2020-10-14 | 2020-10-16 | 233,405 | — | $0 | 365,280 | SEC↗ |
| TANEN DAVID M | Director | C Conversion | 2020-10-14 | 2020-10-16 | 68,831 | — | $0 | 434,111 | SEC↗ |
| TANEN DAVID M | Director | C Conversion | 2020-10-14 | 2020-10-16 | 37,119 | $16.15 | $599.5K | 471,230 | SEC↗ |
| TANEN DAVID M | Director | C Conversion | 2020-10-14 | 2020-10-16 | 231,553 | — | $0 | 363,428 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 1,376,313 | — | $0 | 3,001,984 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 366,299 | $16.15 | $5.92M | 3,368,283 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | P Buy | 2020-10-14 | 2020-10-16 | 450,000 | $19.00 | $8.55M | 3,818,283 | SEC↗ |
| Stampacchia Otello | Director, 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 1,606,220 | — | $0 | 1,625,671 | SEC↗ |
| Nessi Claudio | 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 1,376,313 | — | $0 | 3,001,984 | SEC↗ |
| Nessi Claudio | 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 366,299 | $16.15 | $5.92M | 3,368,283 | SEC↗ |
| Nessi Claudio | 10% Owner | P Buy | 2020-10-14 | 2020-10-16 | 450,000 | $19.00 | $8.55M | 3,818,283 | SEC↗ |
| Nessi Claudio | 10% Owner | C Conversion | 2020-10-14 | 2020-10-16 | 1,606,220 | — | $0 | 1,625,671 | SEC↗ |